{"id":32407,"date":"2021-12-03T13:24:26","date_gmt":"2021-12-03T13:24:26","guid":{"rendered":"https:\/\/insights.greyb.com\/?post_type=ht_kb&p=32407"},"modified":"2025-03-10T06:28:34","modified_gmt":"2025-03-10T06:28:34","slug":"abbott-laboratories-patents","status":"publish","type":"ht_kb","link":"https:\/\/insights.greyb.com\/abbott-laboratories-patents\/","title":{"rendered":"Abbott Patents \u2013 Key Insights and Stats"},"content":{"rendered":"\n

Abbott has a total of 47926 patents globally, out of which 21352 have been granted. Of these 47926 patents, more than 52% patents are active. United States of America is where Abbott has filed the maximum number of patents, followed by Europe and Japan and it also seems reasonable as the biggest market for Abbott is USA. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Abbott.<\/p>\n\n\n\n

Abbott was founded in 1888 by Wallace Calvin Abbott. The company doing business in Hospital & Health Care Industry. The Company offers a wide range of products in Pharmaceuticals, Medical Devices, Nutrition, Biotechnology and Health Diagnostics, etc. As of November 2021, Abbott has a market cap of $227.01 Billion.<\/p>\n\n\n\n

Do read about some of the most popular patents of Abbott which have been covered by us in this article and also you can find Abbott\u2019s patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Abbott\u2019s patent portfolio.<\/p>\n\n\n\n

How many patents does Abbott have?<\/strong><\/h3>\n\n\n\n

Abbott has a total of 47926 patents globally. These patents belong to 11890 unique patent families. Out of 47926 patents, 24836 patents are active.<\/p>\n\n\n\n

How many Abbott patents are Alive\/Dead?<\/strong><\/h3>\n\n\n\n

Worldwide Patents<\/strong><\/p>\n\n\n\n

\"Abbott<\/a><\/figure>\n\n\n\n

How Many Patents did Abbott File Every Year?<\/strong><\/h3>\n\n\n\n
\"Abbott<\/a><\/figure>\n\n\n\n

Are you wondering why there is a drop in patent filing for the last two years? <\/strong>It is because a patent application can take up to 18 months to get published. Certainly, it doesn\u2019t suggest a decrease in the patent filing.<\/p>\n\n\n\n

Year of Patents Filing or Grant<\/strong><\/td>Abbott Applications Filed<\/strong><\/td>Abbott Patents Granted<\/strong><\/td><\/tr>
2011<\/td>3992<\/td>1344<\/td><\/tr>
2012<\/td>2955<\/td>1611<\/td><\/tr>
2013<\/td>2722<\/td>1728<\/td><\/tr>
2014<\/td>2195<\/td>1835<\/td><\/tr>
2015<\/td>1997<\/td>1766<\/td><\/tr>
2016<\/td>1539<\/td>1821<\/td><\/tr>
2017<\/td>1431<\/td>1656<\/td><\/tr>
2018<\/td>1326<\/td>1389<\/td><\/tr>
2019<\/td>941<\/td>1118<\/td><\/tr>
2020<\/td>769<\/td>1026<\/td><\/tr>
2021<\/td>332<\/td>827<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Explore the top-performing drugs that dominate the Pharmaceutical Industry<\/strong><\/h3>\n\n\n\n
Patent Number<\/strong><\/td>Company<\/strong><\/td>Product<\/strong><\/td>Brand<\/strong><\/td>Revenue<\/strong><\/td>Patent Expiry Date<\/strong><\/td><\/tr>
US9174975<\/a><\/td>Sumitomo Pharma<\/td>Lurasidone Hydrochloride<\/td>Latuda<\/td>$1.75B<\/td>Jun-26<\/td><\/tr>
US7612199<\/a><\/td>Alfasigma<\/td>Rifaximin<\/td>Xifaxan<\/td>$1.64B<\/td>Nov-24<\/td><\/tr>
US7902206<\/a><\/td>Alfasigma<\/td>Rifaximin<\/td>Xifaxan<\/td>$1.64B<\/td>Nov-24<\/td><\/tr>
US8158644<\/a><\/td>Alfasigma<\/td>Rifaximin<\/td>Xifaxan<\/td>$1.64B<\/td>Nov-24<\/td><\/tr>
US7371727<\/a><\/td>Ironwood Pharma<\/td>Linaclotide<\/td>Linzess<\/td>$1.00B<\/td>Mar-25<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n
\n

Want to know which drugs are making over $1 Billion annually?<\/h3>\n<\/div>\n
\n
Get the Data<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n

How Many Patents did Abbott File in Different Countries?<\/strong><\/h3>\n\n\n\n
\"Abbott<\/a><\/figure>\n\n\n\n

Countries in which Abbott Filed Patents<\/strong><\/h3>\n\n\n\n
Country<\/strong><\/td>Patents<\/strong><\/td><\/tr>
United States Of America<\/td>15762<\/td><\/tr>
Europe<\/td>5202<\/td><\/tr>
Japan<\/td>3085<\/td><\/tr>
China<\/td>2239<\/td><\/tr>
Canada<\/td>1938<\/td><\/tr>
Australia<\/td>1915<\/td><\/tr>
Mexico<\/td>1043<\/td><\/tr>
Germany<\/td>898<\/td><\/tr>
Spain<\/td>845<\/td><\/tr>
Hong Kong (S.A.R.)<\/td>791<\/td><\/tr>
Brazil<\/td>630<\/td><\/tr>
India<\/td>578<\/td><\/tr>
Israel<\/td>577<\/td><\/tr>
Korea (South)<\/td>537<\/td><\/tr>
Austria<\/td>533<\/td><\/tr>
Singapore<\/td>492<\/td><\/tr>
Taiwan<\/td>446<\/td><\/tr>
Russian Federation<\/td>345<\/td><\/tr>
New Zealand<\/td>312<\/td><\/tr>
South Africa<\/td>277<\/td><\/tr>
United Kingdom<\/td>258<\/td><\/tr>
Argentina<\/td>223<\/td><\/tr>
Costa Rica<\/td>217<\/td><\/tr>
Denmark<\/td>213<\/td><\/tr>
Viet Nam<\/td>208<\/td><\/tr>
Peru<\/td>201<\/td><\/tr>
Philippines<\/td>197<\/td><\/tr>
Poland<\/td>158<\/td><\/tr>
Portugal<\/td>144<\/td><\/tr>
Indonesia<\/td>142<\/td><\/tr>
Sweden<\/td>132<\/td><\/tr>
Dominican Republic<\/td>130<\/td><\/tr>
Uruguay<\/td>124<\/td><\/tr>
Ecuador<\/td>120<\/td><\/tr>
Chile<\/td>113<\/td><\/tr>
Colombia<\/td>110<\/td><\/tr>
Norway<\/td>94<\/td><\/tr>
Slovenia<\/td>92<\/td><\/tr>
Ukraine<\/td>89<\/td><\/tr>
Cyprus<\/td>75<\/td><\/tr>
Malaysia<\/td>67<\/td><\/tr>
Turkey<\/td>63<\/td><\/tr>
Hungary<\/td>60<\/td><\/tr>
Eurasian Patent Organization<\/td>60<\/td><\/tr>
Thailand<\/td>52<\/td><\/tr>
Guatemala<\/td>52<\/td><\/tr>
Croatia<\/td>41<\/td><\/tr>
Ireland<\/td>41<\/td><\/tr>
France<\/td>34<\/td><\/tr>
Serbia<\/td>28<\/td><\/tr>
Czech Republic<\/td>28<\/td><\/tr>
Saudi Arabia<\/td>24<\/td><\/tr>
Lithuania<\/td>23<\/td><\/tr>
Slovakia<\/td>20<\/td><\/tr>
Bulgaria<\/td>18<\/td><\/tr>
Panama<\/td>13<\/td><\/tr>
Montenegro<\/td>12<\/td><\/tr>
Tunisia<\/td>8<\/td><\/tr>
Gulf Cooperation Council<\/td>8<\/td><\/tr>
San Marino<\/td>6<\/td><\/tr>
Morocco<\/td>5<\/td><\/tr>
African Regional Industrial Property Organization<\/td>5<\/td><\/tr>
Netherlands<\/td>4<\/td><\/tr>
El Salvador<\/td>3<\/td><\/tr>
Kazakhstan<\/td>3<\/td><\/tr>
Honduras<\/td>2<\/td><\/tr>
Luxembourg<\/td>2<\/td><\/tr>
Estonia<\/td>2<\/td><\/tr>
Italy<\/td>2<\/td><\/tr>
Georgia<\/td>1<\/td><\/tr>
Yugoslavia\/Serbia and Montenegro<\/td>1<\/td><\/tr>
Belarus<\/td>1<\/td><\/tr>
Nicaragua<\/td>1<\/td><\/tr>
Egypt<\/td>1<\/td><\/tr>
Iceland<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Where are Research Centers of Abbott Patents Located?<\/strong><\/h3>\n\n\n\n
\"Research<\/a><\/figure>\n\n\n\n

10 Best Abbott Patents<\/strong><\/h3>\n\n\n\n

US6560471B1<\/a> is the most popular patent in the Abbott portfolio. It has received 1647 citations so far from companies like Dexcom, kaleo Inc and Aseko Inc<\/p>\n\n\n\n

Below is the list of 10 most cited patents of Abbott:<\/strong><\/p>\n\n\n\n

Publication Number<\/strong><\/td>Citation Count<\/strong><\/td><\/tr>
US6560471B1<\/a><\/td>1647<\/td><\/tr>
US6591125B1<\/a><\/td>1544<\/td><\/tr>
US6197042B1<\/a><\/td>1477<\/td><\/tr>
US7008435B2<\/a><\/td>1270<\/td><\/tr>
US66<\/a>1<\/a>6686B2<\/a><\/td>1251<\/td><\/tr>
US7108709B2<\/a><\/td>1205<\/td><\/tr>
US7081114B2<\/a><\/td>1149<\/td><\/tr>
US6746582B2<\/a><\/td>1049<\/td><\/tr>
US693<\/a>2<\/a>894B2<\/a><\/td>1016<\/td><\/tr>
WO2005115251A1<\/a><\/td>992<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Which Companies are using Abbott Patents to Advance their Research?<\/strong><\/h3>\n\n\n\n

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.<\/p>\n\n\n\n

The top citing companies in the Abbott patent portfolio are Medtronic, Boston Scientific and St Jude Medical.<\/strong><\/p>\n\n\n\n

List of the top forward citing Companies \u2013<\/p>\n\n\n\n

Company<\/strong><\/td>Number of Patents<\/strong><\/td><\/tr>
Medtronic<\/td>946<\/td><\/tr>
Boston Scientific<\/td>673<\/td><\/tr>
St Jude Medical<\/td>663<\/td><\/tr>
Cardiac Pacemakers Inc<\/td>325<\/td><\/tr>
Pacesetter Inc<\/td>318<\/td><\/tr>
Biosense Webster Israel Ltd<\/td>226<\/td><\/tr>
Covidien<\/td>200<\/td><\/tr>
Dexcom<\/td>184<\/td><\/tr>
Cook Medical Technologies Llc<\/td>172<\/td><\/tr>
Philips<\/td>159<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Count of 102 and 103 Type Rejections based on Abbott Patents<\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n

Top Abbott Patents used in Rejecting Most Patent Applications<\/strong><\/h3>\n\n\n\n
Patent Number<\/strong><\/td>Count of Rejected Applications<\/strong><\/td><\/tr>
US8597349B2<\/td>69<\/td><\/tr>
US7612181C1<\/td>69<\/td><\/tr>
US7856264B2<\/td>66<\/td><\/tr>
US8449599B2<\/td>63<\/td><\/tr>
US7250052B2<\/td>60<\/td><\/tr>
US8303505B2<\/td>55<\/td><\/tr>
US7483747B2<\/td>46<\/td><\/tr>
US8514086B2<\/td>38<\/td><\/tr>
US7381184B2<\/td>33<\/td><\/tr>
US7734340B2<\/td>33<\/td><\/tr>
US20070060954A1<\/td>33<\/td><\/tr>
US8679061B2<\/td>32<\/td><\/tr>
US7361473B2<\/td>32<\/td><\/tr>
US9180004B2<\/td>31<\/td><\/tr>
US9186081B2<\/td>28<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Percentage of Abbott US Patent Applications were Granted?<\/strong><\/h3>\n\n\n\n

Abbott (Excluding its subsidiaries) has filed 9567 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 6500 have been granted leading to a grant rate of 72.99%<\/strong>.<\/p>\n\n\n\n

Below are the key stats of Abbott’s patent prosecution at the USPTO.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Which Law Firms Filed Most US Patents for Abbott?<\/strong><\/h3>\n\n\n\n
Law Firm<\/strong><\/td>Total Applications<\/strong><\/td>Success Rate<\/strong><\/td><\/tr>
Abbott Patent Department<\/td>1891<\/td>60.12%<\/td><\/tr>
Abbvie Inc<\/td>710<\/td>93.61%<\/td><\/tr>
Abbott Diabetes Care Inc<\/td>486<\/td>74.02%<\/td><\/tr>
Squire Pb<\/td>479<\/td>72.59%<\/td><\/tr>
Johnson & Johnson Surgical Vision Inc<\/td>468<\/td>87.61%<\/td><\/tr>
Workman Nydegger<\/td>456<\/td>71.46%<\/td><\/tr>
Baker Botts<\/td>444<\/td>89.85%<\/td><\/tr>
One Llp<\/td>303<\/td>76.00%<\/td><\/tr>
Edward H Gorman Jr<\/td>281<\/td>55.47%<\/td><\/tr>
Steven F Weinstock<\/td>222<\/td>27.73%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Abbott’s life-changing technology enables people to live completely and provides information, medicines, and innovations to assist you in managing your health.<\/p>\n\n\n\n

Abbott’s STARLIMS is one such example, its informatics platform is a mission-critical laboratory information management solution (LIMS) programme that was built from the bottom up to facilitate this digital transformation while addressing “technical debt” difficulties. Out-of-date systems being removed from use when laboratory instruments, platforms, and software are upgraded and replaced, but many will still need to be maintained at a large cost in order to access data saved in proprietary formats.<\/p>\n\n\n\n

It gives manufacturing, R&D, and testing labs the capacity to effortlessly navigate the quickly changing technical and data landscape, allowing them to preserve their investments and gain maximum insight from almost every piece of data across the company.<\/p>\n\n\n\n

EXCLUSIVE INSIGHTS COMING SOON<\/strong><\/p>\n\n\n\n

What are Abbott\u2019s key innovation segments?<\/strong><\/p>\n\n\n\n